The new conjugated antibody sacituzumab-govitecan - a new type of drug in which the antibody binds to the chemotherapy to take it directly into the cancer cell, and for them termed 'smart chemotherapy' - significantly extends survival compared to chemotherapy in cancer. triple negative metastatic breast cancer and improves progression-free survival in patients with highly pre-treated metastatic Her2-negative breast cancer.
The data were presented to the Congreso of the American Society of Clinical Oncology (ASCO).
"Today in Italy there are more than 37 thousand people with metastatic breast cancer - says Saverio Cinieri, president of Aiom (Italian Association of Medical Oncology) -. The triple negative form,
which includes 15% of diagnoses, it is the most aggressive form.
The ASCENT study presented at ASCO is important because it demonstrates that, thanks to targeted therapy, it is possible to significantly improve not only overall survival but also the quality of life. "At the congress, the positive results of the study were also announced. Phase III TROPiCS-02 on sacituzumab-govitecan compared to chemotherapy chosen by the physician in patients with HER2 negative metastatic breast cancer: there was a statistically significant 34% reduction in the risk of disease progression or death. "Sacituzumab-govitecan is an extremely innovative drug that exploits the ability of an antibody capable of targeting a specific target on cancer cells,
carrying a powerful chemotherapy drug.
This allows on the one hand a great therapeutic efficacy, on the other hand to reduce the toxicity linked to the exposure of normal cells ", comments Giampaolo Bianchini, head of the Breast Group in the Oncology Department of the San Raffaele Hospital in Milan. And he adds:" This molecule is approved by the American and European regulators for triple-negative metastatic disease, and ASCO has been confirmed to be able to halve the relative risk of death, an unprecedented result in this particular type of particularly aggressive breast cancer. .
We are all awaiting the reimbursement of the drug in Italy ".
other to reduce the toxicity linked to the exposure of normal cells ", comments Giampaolo Bianchini, head of the Breast Group in the Oncology Department of the San Raffaele Hospital in Milan. And he adds:" This molecule is approved by the American and European regulatory bodies for the triple-negative metastatic disease, and ASCO was confirmed to be able to halve the relative risk of death, an unprecedented result in this particular type of particularly aggressive breast cancer.
We are all awaiting the reimbursement of the drug in Italy ".
other to reduce the toxicity linked to the exposure of normal cells ", comments Giampaolo Bianchini, head of the Breast Group in the Oncology Department of the San Raffaele Hospital in Milan. And he adds:" This molecule is approved by the American and European regulatory bodies for the triple-negative metastatic disease, and ASCO was confirmed to be able to halve the relative risk of death, an unprecedented result in this particular type of particularly aggressive breast cancer.
We are all awaiting the reimbursement of the drug in Italy ".
This molecule is approved by the American and European regulators for triple-negative metastatic disease, and ASCO has been confirmed to be able to halve the relative risk of death, an unprecedented result in this particular type of particularly aggressive breast cancer. .
We are all awaiting the reimbursement of the drug in Italy ".
This molecule is approved by the American and European regulators for triple-negative metastatic disease, and ASCO has been confirmed to be able to halve the relative risk of death, an unprecedented result in this particular type of particularly aggressive breast cancer. .
We are all awaiting the reimbursement of the drug in Italy ".
